Aravive Initiates a Phase 2a Clinical Trial of AVB-500 in Patients with Kidney Fibrosis
20 déc. 2019 08h00 HE
|
Aravive, Inc.
HOUSTON, Dec. 20, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, today announced that the company has begun enrolling patients in the Phase 2a...
Aravive Announces Participation at the 2019 Piper Jaffray Healthcare Conference
02 déc. 2019 08h00 HE
|
Aravive, Inc.
HOUSTON, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening...
Aravive Announces Pricing of Public Offering of Common Stock
27 nov. 2019 08h30 HE
|
Aravive, Inc.
HOUSTON, Nov. 27, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), (“Aravive”) a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of...
Aravive Announces Proposed Public Offering of Common Stock
26 nov. 2019 17h14 HE
|
Aravive, Inc.
HOUSTON, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), (“Aravive”) a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of...
Aravive and AstraZeneca Announce Initiation of Randomized Phase 1/2 Study of AVB-500 in Combination with Durvalumab in Patients with Platinum-Resistant Recurrent Epithelial Ovarian Cancer
12 nov. 2019 08h00 HE
|
Aravive, Inc.
HOUSTON and WILMINGTON, Del., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV) and AstraZeneca (NYSE: AZN) today announced that an investigator-sponsored Phase 1/2 clinical trial of...
CORRECTION – Aravive Reports Third Quarter 2019 Financial Results and Provides Recent Corporate Updates
08 nov. 2019 13h11 HE
|
Aravive, Inc.
HOUSTON, Nov. 08, 2019 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Thursday, November 7th by Aravive, Inc. (Nasdaq: ARAV), please note that in the last sentence of the second...
Aravive Reports Third Quarter 2019 Financial Results and Provides Recent Corporate Updates
07 nov. 2019 16h05 HE
|
Aravive, Inc.
HOUSTON, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening...
Aravive Announces Publication of AVB-500 Nonclinical Study in Treatment-Resistant ccRCC Animal Models in Cancer Research
18 oct. 2019 08h00 HE
|
Aravive, Inc.
AVB-500 reduced tumor size and blood vessel density in animal models Study highlights role of GAS6/AXL signaling in promoting tumor angiogenesis through regulation of plasminogen receptor S100A10 ...
Aravive Presents Positive Data from Initial 12 Patients in Phase 1b Portion of its Phase 1b/2 Ovarian Cancer Study of AVB-500 in Late Breaking Oral Presentation at European Society for Medical Oncology Congress in Barcelona
27 sept. 2019 10h15 HE
|
Aravive, Inc.
HOUSTON, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV) today presented positive data from the initial 12 patients of the ongoing Phase 1b portion of the company’s Phase 1b/2 study...
Aravive Announces Participation at the 2019 Cantor Global Healthcare Conference
27 sept. 2019 08h00 HE
|
Aravive, Inc.
HOUSTON, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening...